Q3 Earnings Estimate for CTNM Issued By Leerink Partnrs

Contineum Therapeutics, Inc. (NASDAQ:CTNM) – Equities research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for Contineum Therapeutics in a report released on Thursday, September 25th. Leerink Partnrs analyst F. Khurshid anticipates that the company will earn ($0.67) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Contineum Therapeutics’ current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Contineum Therapeutics’ Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.63) EPS, Q1 2026 earnings at ($0.76) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.85) EPS and FY2026 earnings at ($2.83) EPS.

Contineum Therapeutics (NASDAQ:CTNM) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06).

Other equities analysts have also issued reports about the stock. William Blair assumed coverage on shares of Contineum Therapeutics in a research note on Friday, June 20th. They issued an “outperform” rating on the stock. Leerink Partners started coverage on shares of Contineum Therapeutics in a research report on Thursday, September 25th. They set an “outperform” rating and a $20.00 target price on the stock. Finally, Morgan Stanley raised their target price on shares of Contineum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Monday, August 18th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $22.20.

Contineum Therapeutics Stock Down 0.6%

Shares of Contineum Therapeutics stock opened at $11.75 on Monday. The firm has a market capitalization of $329.49 million, a P/E ratio of -5.34 and a beta of 1.13. Contineum Therapeutics has a 52 week low of $3.35 and a 52 week high of $20.24. The firm’s 50 day moving average is $9.29 and its two-hundred day moving average is $6.26.

Hedge Funds Weigh In On Contineum Therapeutics

Hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Contineum Therapeutics by 90.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,860 shares of the company’s stock worth $86,000 after purchasing an additional 2,783 shares during the period. Bank of America Corp DE lifted its holdings in shares of Contineum Therapeutics by 63.4% during the fourth quarter. Bank of America Corp DE now owns 9,132 shares of the company’s stock worth $134,000 after purchasing an additional 3,542 shares during the period. Strs Ohio acquired a new stake in shares of Contineum Therapeutics during the first quarter worth $27,000. Qube Research & Technologies Ltd acquired a new stake in shares of Contineum Therapeutics during the second quarter worth $43,000. Finally, Marex Group plc acquired a new stake in shares of Contineum Therapeutics during the second quarter worth $45,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).